4t1 crl 2539 cell lines  (ATCC)

Journal: Nature Communications

Article Title: Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions

doi: 10.1038/s41467-024-51197-w

Figure Lengend Snippet: a CoIP assays of WMiApt-1 in blocking the interaction between WDR5 and MYC (biological replicates n = 2). Source data are provided as a Source Data file. b Protein levels of MYC and WDR5 of three human-derived cell lines. c Anti-proliferation effects of WMiApt-1 in three human cell lines The result is determined from three biological replicates, each containing three technical replicates (biological replicates n = 3, mean ± SD, Two-sided Student’s t -test). The 95% confidence intervalare −56.79 to −36.85, −23.20 to −2.945 and −8.267 to −0.7118. Source data are provided as a Source Data file. Source data are provided as a Source Data file. d Schematic diagram illustrating the anti-tumorigenesis experiments in-vivo. Icons from Canva. e Tumor volumes of 4T1 cells treated with WMiApt-1 or control on the fifth day post-implantation (biological replicates n = 5, mean ± SD, Two-sided Student’s t -test). The 95% confidence interval is −8.267 to −0.7118. Source data are provided as a Source Data file.

Article Snippet: MDA-MB-468 (HTB-132), HEK293T (ACS-4500), SKNBE2 (CRL-2271), 4T1 (CRL-2539) cell lines were purchased from ATCC.

Techniques: Blocking Assay, Derivative Assay, In Vivo, Control

Journal: Cancer Immunology Research

Article Title: Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN

doi: 10.1158/2326-6066.CIR-23-1093

Figure Lengend Snippet: CIN drives cGAS-STING–dependent TREX1 upregulation. Immunoblotting for TREX1 and β-actin in the indicated CT26 ( A ), EO771.LMB ( B ), and 4T1 ( C ) cells. D, Quantification of TREX1 relative to corresponding β-actin signal in the indicated cell lines as shown in A–C ; mean ± SD, n = 3 experiments. Two-sided t test was used to determine statistical significance; ****, P < 0.0001; ***, P < 0.001, ns, not significant. E, qRT-PCR of Trex1 expression in the indicated cell lines; mean ± SD, n = 3–4 technical replicates. Two-sided t test was used to determine statistical significance; ****, P < 0.0001; *, P < 0.05. F, Schematic representation of the in vitro assay for TREX1 exonuclease activity. A dsDNA substrate with a 5′ TEX615 fluorophore and an adjacent Iowa Black quencher is incubated with cell lysate. TREX1 exonuclease activity liberates TEX615 fluorescence by eliminating Iowa Black quenching. G, Time course of TREX1 exonuclease activity on dsDNA substrate as in F ; mean ± SD, representative example from n = 3 experiments. One-way ANOVA was used to determine statistical significance; ****, P < 0.0001.

Article Snippet: CT26 (catalog no.CRL-2638), EO771.LMB (catalog no.CRL-3405), and 4T1 (catalog no. CRL-2539) cell lines were purchased from the ATCC.

Techniques: Western Blot, Quantitative RT-PCR, Expressing, In Vitro, Activity Assay, Incubation, Fluorescence

Journal: Cancer Immunology Research

Article Title: Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN

doi: 10.1158/2326-6066.CIR-23-1093

Figure Lengend Snippet: TREX1 induction limits cGAS-STING activation in chromosomally unstable cancer cells. ELISA analysis of intracellular cGAMP production in the indicated CT26 ( A ), EO771.LMB ( B ), and 4T1 ( C ) cells; mean ± SD, n = 4–8 biological replicates. One-way ANOVA was used to determine statistical significance; ***, P < 0.001; **, P < 0.01. ELISA analysis of extracellular cGAMP production in the indicated CT26 ( D ), EO771.LMB ( E ), and 4T1 ( F ) cells; mean ± SD, n = 4–8 biological replicates, nd, not detected. One-way ANOVA was used to determine statistical significance; ***, P < 0.001; *, P < 0.05. G, Immunoblotting for TBK1, phospho-TBK1(S172), IRF3, phospho-IRF3 (S396) and β-actin in the indicated EO771.LMB cells.

Article Snippet: CT26 (catalog no.CRL-2638), EO771.LMB (catalog no.CRL-3405), and 4T1 (catalog no. CRL-2539) cell lines were purchased from the ATCC.

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Western Blot

Journal: Cancer Immunology Research

Article Title: Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN

doi: 10.1158/2326-6066.CIR-23-1093

Figure Lengend Snippet: TREX1 induction promotes tumor growth. A, Growth curves of indicated injected CT26 tumors; datapoints, mean ± SEM, n = 6–7 animals per group. B, Survival of BALB/c animals after injection with indicated CT26 tumor cells; n = 6–7 animals per group. C, Growth curves of indicated orthotopically transplanted EO771.LMB tumors; datapoints, mean ± SEM, n = 10 animals per group. D, Survival of C57BL/6J animals after orthotopic transplantation with indicated EO771.LMB tumor cells; n = 10 animals per group. E, Growth curves of indicated orthotopically transplanted 4T1 tumors; datapoints, mean ± SEM, n = 10 animals per group. F, Survival of BALB/c animals after orthotopic transplantation with indicated 4T1 tumor cells; n = 10 animals per group. Two-sided t test was used to determine statistical significance at the last timepoint in A , C , and E ; ****, P < 0.0001; ***, P < 0.001, ns, not significant. log-rank test was used to determine statistical significance in B , D , and F ; ****, P < 0.0001; ***, P < 0.001; ns, not significant.

Article Snippet: CT26 (catalog no.CRL-2638), EO771.LMB (catalog no.CRL-3405), and 4T1 (catalog no. CRL-2539) cell lines were purchased from the ATCC.

Techniques: Injection, Transplantation Assay

Journal: Cancer Immunology Research

Article Title: Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN

doi: 10.1158/2326-6066.CIR-23-1093

Figure Lengend Snippet: TREX1 induction reduces immunotherapy efficacy. Growth curves of indicated orthotopically transplanted EO771.LMB ( A ) and 4T1 ( B ) tumors upon treatment with anti-PD-1 or corresponding isotype control; datapoints, mean ± SEM, n = 9–10 animals per group. Two-sided t test was used to determine statistical significance at the last timepoint; ****, P < 0.0001; ***, P < 0.001; ns, not significant. Survival of C57BL/6J or BALB/c animals after orthotopic transplantation with indicated EO771.LMB ( C ) or 4T1 ( D ) tumor cells following treatment with anti-PD-1 or corresponding isotype control; n = 9–10 animals per group. log-rank test was used to determine statistical significance; ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant.

Article Snippet: CT26 (catalog no.CRL-2638), EO771.LMB (catalog no.CRL-3405), and 4T1 (catalog no. CRL-2539) cell lines were purchased from the ATCC.

Techniques: Transplantation Assay

Journal: Cancer & Metabolism

Article Title: Disrupting Na + ion homeostasis and Na + /K + ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo

doi: 10.1186/s40170-024-00343-5

Figure Lengend Snippet: Metabolic characterization and response to ouabain treatment on [Na + ] i . a Principal component analysis of intracellular metabolites (mean values given in Supplementary Table S2). Intracellular concentrations of b lactate (left panel) and c phosphocholine (right panel) were significantly higher in all cancer cells with respect to control epithelial cells ( n = 5). Extracellular metabolite concentrations of d glucose, e glutamine and f lactate after 24 h cell culture. Respective metabolite concentration from fresh media were subtracted such that negative concentrations refer to metabolite consumption while positive concentrations refer to production ( n = 5). g MTT cytotoxicity assay dose response curves following 24 h treatment with ouabain. Measured EC 50 values were: 4T1: 40 µM, MDA-MB-231: 0.4 µM, HCC1954: 0.2 µM, MCF-7: 0.04 µM. h Cell viability in response to 1 µM ouabain for 1 h measured by trypan blue exclusion assay measured no change in cell viability. i Representative TQF 23 Na NMR spectra showing proportionality with cell number. The Tm-DOTP reference peak is from the internal standard. j Quantification of TQF 23 Na NMR relative to cell number and cell volume. Baseline [Na + ] i was higher in all cancer cells with respect to control epithelial cells ( n = 5). Treatment with 1 µM ouabain for 1 h led to a significant increase in [Na + ] i in all human cancer cell lines compared to vehicle control ( n = 5). [Na + ] i was unchanged in the murine 4T1 cell line following 1 h treatment with 1 µM ouabain, ( p = 0.7, n = 5). Significance was assessed using a two-tailed unpaired t-test, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data plotted as mean ± SD

Article Snippet: Human cell lines MDA-MB-231 (CRM-HTB-26); MCF-7 (HTB-22); HCC1954 (CRL-2338) and 4T1 (CRL-2539) mouse cell line were obtained from American Type Culture Collection (ATCC).

Techniques: Cell Culture, Concentration Assay, Cytotoxicity Assay, Trypan Blue Exclusion Assay, Two Tailed Test

Journal: Cancer & Metabolism

Article Title: Disrupting Na + ion homeostasis and Na + /K + ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo

doi: 10.1186/s40170-024-00343-5

Figure Lengend Snippet: Extracellular acidification rate with NKA inhibition . a Seahorse XFe24 glycolytic stress test of extracellular change in pH for the MDA-MB-231 cancer cells (± SEM representing biological reproducibility of n = 3 biological repeats where each n = 3 technical repeats were first averaged). Complete time courses for the other cell lines are given in Supplementary Fig. S8. The stress test comprised 10 mM glucose, 1 μM oligomycin, and 100 mM 2-deoxy-D-glucose indicated by arrows. b Oxygen consumption rate (OCR) measured simultaneously with the ECAR data in panel a . c Plot of the measured ECAR glycolytic rate vs OCR during the 10 mM glucose time window defined in Supplementary Fig. S6 ( n = 3 biological repeats each with n = 3 technical repeats) showing a reduction in glycolytic rate and no change in OCR. Quantified extracellular acidification rate corresponding to glycolytic rates during the 10 mM glucose time window (left panels) and their corresponding OCR (right panels), in control and ouabain treated cells: d 4T1: ECAR ( p = 0.24), OCR ( p = 0.39); e MDA-MB-231: ECAR decreased by 52% ( p = 0.006), OCR ( p = 0.40); f HCC1954: ECAR decreased by 21% ( p = 0.08), OCR ( p = 0.66); g MCF-7: ECAR decreased by 38% ( p = 0.015), OCR ( p = 0.16). n = 3 biological repeats each with n = 3 technical repeats, significance was assessed using a nested unpaired t-test. ns p > 0.05, * p < 0.05, ** p < 0.01

Article Snippet: Human cell lines MDA-MB-231 (CRM-HTB-26); MCF-7 (HTB-22); HCC1954 (CRL-2338) and 4T1 (CRL-2539) mouse cell line were obtained from American Type Culture Collection (ATCC).

Techniques: Inhibition

Journal: Cancer & Metabolism

Article Title: Disrupting Na + ion homeostasis and Na + /K + ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo

doi: 10.1186/s40170-024-00343-5

Figure Lengend Snippet: Glycolytic flux measured with 2 H-NMR. a Time-series of 2 H-NMR spectra showing metabolism of [6,6- 2 H 2 ] d -glucose to [3,3- 2 H 2 ] l -lactate by 4T1 cells in suspension. No 2 H label was lost to HOD, serving as an internal chemical shift and intensity standard at 16.7 mM. Time course and empirical fits performed in Matlab of the normalized peak integrals of the [6,6- 2 H 2 ] d -glucose and [3,3- 2 H 2 ] l -lactate spectral peaks: b 4T1 cells and c MDA-MB-231 cells for vehicle control (filled symbols) and ouabain treated (open symbols). d Quantified glycolytic flux in MCF-10A cells was 0.020 ± 0.003 nmol (pL cells) −1 s −1 ( n = 9). 4T1 cells had a higher baseline glycolytic rate of 0.043 ± 0.007 nmol (pL cells) −1 s −1 ( n = 8) and unchanged rate after ouabain treatment, 0.045 ± 0.010 nmol (pL cells) −1 s −1 ( n = 9, p = 0.6949). Human breast cancer cells all showed higher baseline glycolytic rates than control epithelial cells, MDA-MB-231: 0.054 ± 0.003 nmol (pL cells) −1 s −1 ( n = 7); HCC1954: 0.034 ± 0.006 nmol (pL cells) −1 s −1 ( n = 7); MCF-7: 0.031 ± 0.006 nmol (pL cells) −1 s −1 ( n = 7). Human cells showed a decreased glycolytic rate following ouabain-treatment vs vehicle control, MDA-MB-231: 0.020 ± 0.004 nmol (pL cells) −1 s −1 ( n = 7; p < 0.0001); HCC1954: 0.019 ± 0.008 nmol (pL cells) −1 s −1 ( n = 6; p = 0.004); MCF-7: 0.023 ± 0.003 nmol (pL cells) −1 s −1 ( n = 5; p = 0.029). e Schematic of the proposed mechanism of the effect of ouabain inhibition of NKA on glycolytic flux (Figure created using BioRender.com). ns p > 0.05, * p < 0.05, ** p < 0.01, **** p < 0.0001. Data plotted as mean ± SD

Article Snippet: Human cell lines MDA-MB-231 (CRM-HTB-26); MCF-7 (HTB-22); HCC1954 (CRL-2338) and 4T1 (CRL-2539) mouse cell line were obtained from American Type Culture Collection (ATCC).

Techniques: Suspension, Inhibition

Journal: Cancer & Metabolism

Article Title: Disrupting Na + ion homeostasis and Na + /K + ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo

doi: 10.1186/s40170-024-00343-5

Figure Lengend Snippet: Glycolytic flux affected by intracellular [Na] i and NKA function. a Schematic of the proposed mechanism of the effect of gramicidin-A on [Na + ] i and glycolysis. Gramicidin introduces an artificial Na + leak, increasing [Na + ] i and glycolytic metabolism (Figure created using BioRender.com). b 23 Na TQF spectra showing the intracellular [Na + ] i peak relative to a reference capillary in MDA-MB-231 cells following membrane permeabilization with gramicidin and varying concentrations of titrated extracellular [Na + ] e . c Quantification of TQF 23 Na NMR spectra (proportional to [Na + ] i ) following exposure to isotonic solutions of titrated [Na + ] e ( n = 4), for 4T1 cells and MDA-MB-231 cells. d Quantification of glycolytic fluxes measured by the rate of [6,6- 2 H 2 ] d -glucose to [3,3- 2 H 2 ] l -lactate conversion at different concentrations of titrated [Na + ] i in murine 4T1 and human MDA-MB-231 breast cancer cells ( n = 4). e Glycolytic fluxes in panel d replotted as a function of pump current derived from the analytical expression given by Silverman et al. f Glycolytic flux measured at the highest concentration of 70 mM [Na + ] e following treatment with 1 µM ouabain treatment was not significantly altered in murine 4T1 cells but was significantly decreased in human MDA-MB-231 cells. ns p > 0.05, **** p < 0.0001. Data plotted as mean ± SD

Article Snippet: Human cell lines MDA-MB-231 (CRM-HTB-26); MCF-7 (HTB-22); HCC1954 (CRL-2338) and 4T1 (CRL-2539) mouse cell line were obtained from American Type Culture Collection (ATCC).

Techniques: Membrane, Derivative Assay, Expressing, Concentration Assay

Journal: International Journal of Molecular Sciences

Article Title: Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

doi: 10.3390/ijms25105392

Figure Lengend Snippet: EZH2 knockout (KO) and overexpression (OE) cell clones were generated from the parent wild-type (WT) 4T1 TNBC line. ( A ) Western blots (L indicates protein ladder) and ( B ) densitometric analysis comparing 11 clones from each EZH2 KO (upper panel) and EZH2 OE (lower panel) lines to the 4T1 WT line (2 sets of blots for each), with alpha-tubulin as the normalization control. ( C ) Comparison of EZH2 protein expression between KO (blue squares) and OE (red triangles) groups by Wilcoxon rank-sum test, **** p < 0.0001.

Article Snippet: The parent WT 4T1 (CRL-2539) cell line [ ] was purchased from ATCC and cultured at 37 °C and 5% CO 2 in DMEM high-glucose medium (Sigma Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, HyClone, purchased from Avantor, Radnor, PA, USA), 1% HEPES (Thermo Fisher Scientific, Hampton, NH, USA), 1% L-glutamine (Sigma Aldrich), and penicillin–streptomycin (100 U mL −1 , Sigma Aldrich).

Techniques: Knock-Out, Over Expression, Clone Assay, Generated, Western Blot, Comparison, Expressing

Journal: International Journal of Molecular Sciences

Article Title: Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

doi: 10.3390/ijms25105392

Figure Lengend Snippet: In vitro replicative and invasive behaviors of EZH2 KO and EZH2 OE compared to parent WT 4T1 cells. ( A ) Counts of 4T1 WT, EZH2 KO, and EZH2 OE lines over 72 h of growth in 2D plates. ( B ) Representative images of spheroid for 4T1 WT, EZH2 KO, and EZH2 OE lines, and quantification of ( C ) circularity and ( D ) invasive area over 72 h of growth in a 3D invasion assay (n = 8 spheroids per group). Comparisons across groups and timepoints are by two-way ANOVA with Tukey’s post-hoc test and shown as * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: The parent WT 4T1 (CRL-2539) cell line [ ] was purchased from ATCC and cultured at 37 °C and 5% CO 2 in DMEM high-glucose medium (Sigma Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, HyClone, purchased from Avantor, Radnor, PA, USA), 1% HEPES (Thermo Fisher Scientific, Hampton, NH, USA), 1% L-glutamine (Sigma Aldrich), and penicillin–streptomycin (100 U mL −1 , Sigma Aldrich).

Techniques: In Vitro, Invasion Assay

Journal: International Journal of Molecular Sciences

Article Title: Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

doi: 10.3390/ijms25105392

Figure Lengend Snippet: In vitro surface phenotype and secreted factors by EZH2 KO and EZH2 OE compared to parent WT 4T1 cells. ( A ) 4T1 WT (black circles), EZH2 KO (blue squares), and EZH2 OE (red triangles) lines were cultured in DMEM for 24 h and analyzed for the surface expression of relevant surface markers by flow cytometry (six repeats, see Methods and for details). ( B ) Culture supernatants were screened for relevant extracellular mediators via mesoscale assay (four repeats). Comparison between groups is by one-way ANOVA with Tukey’s post-hoc test and shown as * p < 0.05, ** p < 0.01.

Article Snippet: The parent WT 4T1 (CRL-2539) cell line [ ] was purchased from ATCC and cultured at 37 °C and 5% CO 2 in DMEM high-glucose medium (Sigma Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, HyClone, purchased from Avantor, Radnor, PA, USA), 1% HEPES (Thermo Fisher Scientific, Hampton, NH, USA), 1% L-glutamine (Sigma Aldrich), and penicillin–streptomycin (100 U mL −1 , Sigma Aldrich).

Techniques: In Vitro, Cell Culture, Expressing, Flow Cytometry, Comparison

Journal: International Journal of Molecular Sciences

Article Title: Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

doi: 10.3390/ijms25105392

Figure Lengend Snippet: In vivo primary tumor growth and lung metastasis by EZH2 KO and EZH2 OE compared to parent WT 4T1 cells. ( A ) Experimental timeline of 4T1 WT, EZH2 KO, and EZH2 OE injections in mice. ( B ) Growth of 4T1 WT, EZH2 KO, and EZH2 OE primary tumors over 21 days post-injection (n = 6–7 mice per group). Comparisons across groups and timepoints are by two-way ANOVA with Tukey’s post-hoc test and shown as * p < 0.05 and ** p < 0.01 (brackets). Comparison between groups at each timepoint is by one-way ANOVA and shown as * p < 0.05 (as indicated for WT vs. EZH2 KO and EZH2 KO vs. EZH2 OE, above each timepoint). ( C ) Lung metastasis assays for 4T1 WT, EZH2 KO, and EZH2 OE lines. Comparisons between groups are by one-way ANOVA with Tukey’s post-hoc test and shown as ** p < 0.01 and *** p < 0.001.

Article Snippet: The parent WT 4T1 (CRL-2539) cell line [ ] was purchased from ATCC and cultured at 37 °C and 5% CO 2 in DMEM high-glucose medium (Sigma Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, HyClone, purchased from Avantor, Radnor, PA, USA), 1% HEPES (Thermo Fisher Scientific, Hampton, NH, USA), 1% L-glutamine (Sigma Aldrich), and penicillin–streptomycin (100 U mL −1 , Sigma Aldrich).

Techniques: In Vivo, Injection, Comparison

Journal: International Journal of Molecular Sciences

Article Title: Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

doi: 10.3390/ijms25105392

Figure Lengend Snippet: In vivo primary tumor infiltration by neutrophils and CD4+ and CD8+ T cells for EZH2 KO and EZH2 OE compared to parent WT 4T1 cells. ( A ) Flow cytometry strategy for gating of infiltrating leukocyte subsets in 4T1 WT, EZH2 KO, and EZH2 OE primary tumors, with sequential steps 1 (leukocytes), 2 (live cells), 3 (singlets), 4 (granulocytes, including mature neutrophils, immature neutrophils, and eosinophils), 5 (non-granulocytes), 6 (T cells), and 7 (CD4+ and CD8+). ( B ) Relative percentages of infiltrating neutrophils and CD4+ and CD8+ cells among live leukocytes (top), and ratios between these subsets (bottom) in 4T1 WT (black circles), EZH2 KO (blue squares), and EZH2 OE (red triangles) primary tumors. Comparisons between groups are by one-way ANOVA with Tukey’s post-hoc test and shown as * p < 0.05 and ** p < 0.01.

Article Snippet: The parent WT 4T1 (CRL-2539) cell line [ ] was purchased from ATCC and cultured at 37 °C and 5% CO 2 in DMEM high-glucose medium (Sigma Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, HyClone, purchased from Avantor, Radnor, PA, USA), 1% HEPES (Thermo Fisher Scientific, Hampton, NH, USA), 1% L-glutamine (Sigma Aldrich), and penicillin–streptomycin (100 U mL −1 , Sigma Aldrich).

Techniques: In Vivo, Flow Cytometry

Journal: Nature Communications

Article Title: Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery

doi: 10.1038/s41467-024-46331-7

Figure Lengend Snippet: a A table delineating the physicochemical characterizations of DOX/Lipo with eq. 35 mol % Chol (eq. 64.4 mol % Chol for DOX/Lipo-PChcPC) and 5 mol % DSPE-PEG 2K (n = 3 independent experiments). b – f anti-TNBC effects in metastatic orthotopic 4T1-Luc2 tumor mouse model. A total of 2 × 10 5 cells were injected into the 4 th mammary fat pad of BABL/c mice (n = 5 mice) . On day 15, the mice with primary tumors ~200 mm 3 ( b ) received an i.v. administration of various DOX/Lipo or Doxil at 15 mg DOX/kg. c Average tumor growth curves measured by a digital caliper. d mice BLI on day 15, 20, 29, and 35 by Lago optical imaging. Ex vivo lung metastasis BLI from all 5 mice in each group ( e ) and tumor-bearing mice images ( f ) were taken on day 35. Data in a (right portion), c (n = 5 mice) are expressed as mean ± s.d. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test; survival curves were compared using the log-rank Mantel–Cox test. Source data are provided as a Source Data file.

Article Snippet: CT26 (Cat. ATCC CRL-2638) and 4T1 (Cat. CRL-2539) cell lines were obtained from UACC; 4T1-Luc2 (Cat. CRL-2539-LUC2) cells were purchased from ATCC; SU­DHL­4 (Cat. CRL-2957) cell was provided by Professor Catharine Smith at The University of Arizona; these cell lines were cultured in complete RPMI-1640 medium.

Techniques: Injection, Optical Imaging, Ex Vivo

Journal: Cancer Gene Therapy

Article Title: The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model

doi: 10.1038/s41417-024-00735-1

Figure Lengend Snippet: A The primary 4T1 tumor growth was measured by tumor volume for 23 days post cell injection. B Weights of primary tumors at the terminal point were shown (Day 25). C Shown was microscopic lung metastasis analysis. D Representative images of H&E-stained lung sections of the buffer and each treatment group were shown. *Indicates the site of lung micrometastases and macrometastases. Magnification is indicated by scale bars (the scale bar for low magnification images is 1 mm; that for high magnification is 250 µm). n = 4 to 6 for each group. Significant differences by two-way ANOVA ( A ), t-tests ( B ), or one-way ANOVA with Bonferroni’s multiple comparisons tests ( C ) are shown as: * p < 0.05, ** p < 0.01, *** p < 0.001, or **** p < 0.0001.

Article Snippet: ATCC STR profiling test for cell line authentication was recently performed with the result of 98% match of the database profile of ATCC 4T1 cell line (CRL-2539) (ATCC STR profiling test FTA Barcode: MUSA3575; Sales Order: SO2111801; Completed: 11/30/2023).

Techniques: Injection, Staining